Associated Papers
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).
Garg PK et al.
Atherosclerosis, 2018
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Gregson JM et al.
European Journal of Preventive Cardiology, 2017
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A et al.
Plos One, 2017
Coronary heart disease and genetic variants with low phospholipase A2 activity.
Polfus LM et al.
The New England Journal of Medicine, 2015
Integrated analysis of germline and somatic variants in ovarian cancer.
Kanchi KL et al.
Nature Communications, 2014
24448499 (PubMed )
Supplement: NIHMS551112-supplement-13.xlsx › S_Data_12
Select a paper to view details